NASDAQ:PAVM PAVmed (PAVM) Stock Price, News & Analysis $6.36 -0.05 (-0.70%) Closing price 03:59 PM EasternExtended Trading$6.33 -0.03 (-0.39%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About PAVmed Stock (NASDAQ:PAVM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PAVmed alerts:Sign Up Key Stats Today's Range$6.00▼$6.4750-Day Range$6.21▼$10.7452-Week Range$6.00▼$28.44Volume9,812 shsAverage Volume655,191 shsMarket Capitalization$6.33 millionP/E RatioN/ADividend YieldN/APrice Target$65.00Consensus RatingHold Company Overview PAVmed Inc. is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology. Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions. The company completed its initial public offering in 2017 and maintains research, development and regulatory operations in North America and strategic partnerships in Europe. PAVmed’s multidisciplinary team leverages clinical insights, engineering expertise and regulatory know-how to shepherd devices from concept through pivotal studies and commercialization. PAVmed’s executive leadership brings together seasoned professionals from the medical device, clinical practice and regulatory sectors. The management team emphasizes streamlined regulatory pathways and robust clinical trial design, seeking to deliver less-invasive treatment options that address high unmet needs. Though based in the United States, the company’s regulatory clearances and distribution agreements extend into key international markets. Looking ahead, PAVmed is focused on driving commercial adoption of its approved devices while advancing its mid- and late-stage programs toward pivotal data readouts and regulatory submissions. By targeting areas where minimally invasive approaches can improve patient outcomes and reduce healthcare costs, the company aims to establish sustainable growth through a diversified pipeline of differentiated medical technologies.AI Generated. May Contain Errors. Read More PAVmed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScorePAVM MarketRank™: PAVmed scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingPAVmed has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialPAVmed has a consensus price target of $65.00, representing about 922.8% upside from its current price of $6.36.Amount of Analyst CoveragePAVmed has only been the subject of 2 research reports in the past 90 days.Read more about PAVmed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for PAVmed are expected to remain at ($3.19) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of PAVmed is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PAVmed is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPAVmed has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.05% of the float of PAVmed has been sold short.Short Interest Ratio / Days to CoverPAVmed has a short interest ratio ("days to cover") of 1.17, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PAVmed has recently increased by 16.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPAVmed does not currently pay a dividend.Dividend GrowthPAVmed does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.12 News SentimentPAVmed has a news sentiment score of -0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for PAVmed this week, compared to 2 articles on an average week.MarketBeat Follows4 people have added PAVmed to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PAVmed insiders have not sold or bought any company stock.Percentage Held by Insiders13.40% of the stock of PAVmed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions19.93% of the stock of PAVmed is held by institutions.Read more about PAVmed's insider trading history. Receive PAVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PAVM Stock News HeadlinesPAVmed Inc (PAVM) Q1 2026 Earnings Call Highlights: Strategic Restructuring and Growth ...May 15, 2026 | finance.yahoo.comPAVmed Inc.: PAVmed Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 15, 2026 | finanznachrichten.deMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity for $2.6 billion and Twitter for $44 billion. Now one small company makes the equipment his Colossus supercomputer - a million GPUs consuming nearly $1 billion a month in power - cannot run without. Analyst Dylan Jovine has identified the name and ticker. For investors who own shares before a potential move, the math could be significant.May 20 at 1:00 AM | Behind the Markets (Ad)PAVmed (PAVM) Q4 2025 Earnings TranscriptMay 15, 2026 | finance.yahoo.comPAVmed targets Varis FDA submission by end of 2026 while evaluating new assets following cap table cleanupMay 15, 2026 | seekingalpha.comPAVmed Inc. (PAVM) Q1 2026 Earnings Call TranscriptMay 15, 2026 | seekingalpha.comPAVmed Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 15, 2026 | prnewswire.comLucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 14, 2026 | prnewswire.comSee More Headlines PAVM Stock Analysis - Frequently Asked Questions How have PAVM shares performed this year? PAVmed's stock was trading at $7.33 at the start of the year. Since then, PAVM shares have decreased by 13.3% and is now trading at $6.3550. How were PAVmed's earnings last quarter? PAVmed Inc. (NASDAQ:PAVM) issued its earnings results on Friday, May, 15th. The company reported ($1.17) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by $0.48. The business earned $0.02 million during the quarter, compared to analysts' expectations of $0.07 million. PAVmed had a negative trailing twelve-month return on equity of 146.19% and a negative net margin of 21,914.12%. Read the conference call transcript. When did PAVmed's stock split? PAVmed's stock reverse split on the morning of Friday, January 2nd 2026.The 1-30 reverse split was announced on Tuesday, December 30th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 31st 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of PAVmed? Shares of PAVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PAVmed own? Based on aggregate information from My MarketBeat watchlists, some other companies that PAVmed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), Pfizer (PFE). Company Calendar Last Earnings5/15/2026Today5/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 PAVM's financial health is in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:PAVM CIK1624326 Webwww.pavmed.com Phone(212) 949-4319FaxN/AEmployees90Year Founded2014Price Target and Rating Average Price Target for PAVmed$65.00 High Price Target$65.00 Low Price Target$65.00 Potential Upside/Downside+922.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($37.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$400 thousand Net Margins-21,914.12% Pretax Margin-26,065.88% Return on Equity-146.19% Return on Assets-18.39% Debt Debt-to-Equity Ratio0.70 Current Ratio2.02 Quick Ratio2.02 Sales & Book Value Annual Sales$85 thousand Price / Sales74.47 Cash FlowN/A Price / Cash FlowN/A Book Value$21.32 per share Price / Book0.30Miscellaneous Outstanding Shares996,000Free Float863,000Market Cap$6.33 million OptionableOptionable Beta0.64 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:PAVM) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredFed story no one is tellingJ.P. Morgan's Private Bank quietly advised 333 billionaire families to move 60% of their portfolios into alter...TradeSmith | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PAVmed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PAVmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
